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laparotomy (c-RRRtM) and laparoscopy (L-RRRtM) is described concerning resection of residual 










in the c-RRRtM group (p < 0.001). Laparoscopic resection of RRTM for advanced NSTGCT is feasible 
and an oncologically safe option in appropriately selected patients.
The introduction of platinum-based chemotherapy to treat advanced nonseminomatous germ cell tumor 
(NSTGCT) has impacted survival rates greatly, with an overall 10-year survival rate of up to 90%1,2. Surgery plays 
a pivotal role in the treatment of residual retroperitoneal tumor masses (RRTM) as well as pulmonary residual 
disease in NSTGCT and is aimed at resecting viable germ cell cancer tissue and/or teratoma3–7. The extent of 
surgery has remained controversial for many years, with a surgical spectrum varying from a full bilateral retrop-
eritoneal lymph node dissection (RPLND) to a more limited approach with resection of visible abnormal retrop-
eritoneal tumor masses8,9. Today’s literature supports that a modified post chemotherapy RPLND, e.g. resection of 
well-defined residual retroperitoneal tumor masses (RRRTM), is a safe oncological procedure, with less morbidity 
and it conserves sexual functioning in the majority of these patients10–12.
Classically, RPLND or RRRTM was executed through a midline laparotomy. Laparoscopic RPLND 
(L-RPLND) was first performed in 1992. In the past decade, it has emerged as an alternative to reduce morbidity 
associated with conventional open surgery using the same boundaries of dissection. Laparoscopic surgery is 
mainly described in literature for stage I disease as a diagnostic procedure and for the resection of low volume dis-
ease13–16. In an earlier pilot study, the Groningen study group showed that the laparoscopic approach was feasible, 
with a low rate of retroperitoneal relapse in advanced testicular cancer in properly selected patients17. So far, there 
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are no large consecutive series of disseminated testicular cancer patients described with respect to the results of 
adjunctive surgery; e.g., conventional versus laparoscopic resection of RRTM. For the laparoscopic resection of 
RRTM to be considered a safe alternative oncologic procedure compared to conventional open surgery in patients 
with advanced NSTGCT, long-term follow up assessments in a larger cohort are required.
The current study aimed to describe the 10-year experience of the Comprehensive Cancer Center of the 
University Medical Center Groningen UMCG with conventional resection of RRTM (C-RRRTM) and laparo-
scopic resection of RRTM (L-RRRTM) in a consecutive series of patients and compared first the intra and post-
operative morbidity data of L-RRRTM group with the C-RRRTM group and secondly focused on long-term 
oncologic outcome of both surgical procedures. Furthermore, were the oncological and technical boundaries for 
laparoscopic management in the field of adjunctive surgery after cisplatin combination chemotherapy in patients 
with testicular cancer defined.
Methods
The institutional review board of the UMCG was consulted, and they confirmed that no formal written waiver for 
the need of ethics approval was required because of the retrospective design of the study and anonymised data.
A total of 296 disseminated patients with NSTGCT were treated at the Department of Urology, Surgical 
Oncology and Medical Oncology, of the UMCG between 2005 and 2015. Of these 296 patients, 150 underwent 
resection of RRTM after 3 or 4 cycles of cisplatin based combination chemotherapy. All patients were prospec-
tively studied. Until 2004, the UMCG gold standard was RRRTM using a conventional midline laparotomy. 
The results of this policy with respect to the oncological, sexual, and psychosocial outcomes were previously 
described4,5,12. Laparoscopic resection of RRTM was introduced at the UMCG in 2004. The selection criteria for 
L-RRRTM were based on tumor size and the localization of the residual mass and were described previously in 
the pilot report17. In short, patients were candidates for a laparoscopic approach if the RRTM was less than 5 cm 
in diameter and located ventrally or laterally from the aorta, inferior caval vein, or iliac vessels. Incidentally, a 
slightly larger RRTM up to max 7 cm at a favorable para-aortic anatomical location was accepted for laparoscopic 
resection. In these cases, a higher risk for conversion was considered and discussed with the patient before the 
procedure. Patients with a RRTM posterior to the great vessels and/or a tumor mass larger than 5 cm were not 
considered candidates for laparoscopy. A flow diagram of the current series of 296 patients with NSTGCT sched-
uled for L-RRRTM or C-RRRTM is presented in Fig. 1. Also presented in Fig. 1 are the number of converted 
procedures from laparoscopy to an open procedure.
Surgical procedure. The surgical procedure, excising only visible abnormal retroperitoneal tumor masses, 
has been extensively described previously in the feasibility report17. The laparoscopic resections were performed 
by 5 experienced laparoscopic surgical oncologists together with dedicated surgical oncology fellows. Key points 
regarding the laparoscopic procedure are that patients were positioned in the “French” or in a half-right lateral 
position depending on the localization of the RRTM4,5,17. Surgical resection comprised only the resection of the 
RRTM and conversion was performed in case of technical difficulties due to patient and/or tumor characteristics 
and/or complications.
Figure 1. Patient flow chart of all 296 consecutive NSTGCT patients with disseminated disease treated with 3 
of 4 courses of cisplatin based combination chemotherapy at the UMCG between 2005 and 2015.
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Factors leading to conversion were classified into two categories; reactive conversion (RC), which is defined as 
one that follows an intraoperative event such as bleeding, and pre-emptive conversion (PC), which is defined as a 
conversion undertaken to avoid complications such as unclear anatomy, obesity, and a time-consuming laparos-
copy procedure without any ‘surgical progress’ during the resection of the RRTM.
Conventional resection was performed with the same oncological principles, excising only visible abnormal 
retroperitoneal tumor masses3–7.
postoperative procedure. Direct postoperative follow up was performed at the UMCG by the Department 
of Surgical Oncology and long-term follow up by the Department of Medical Oncology according to the guide-
lines of the European Society for Medical Oncology (ESMO). Within this protocol, a monthly clinical and tumor 
marker evaluation was performed over the first year, followed by a gradually tapering schedule, with annual eval-
uations from years 5 to 10. Computed tomography was done 6, 12, and 24 months after complete resections and 
6, 12, 24, and 60 month after incomplete resections.
Statistical analysis and assessment of complications. A prospective dataset, including the previ-
ously described patients17, was constructed of all patients undergoing L-RRRTM or C-RRRTM from 2005 to 
2015 comprising all patient and treatment-related information. Intra- and post-operative complications were 
categorized using administrative and electronic medical records. Patients were asked with regular intervals about 
symptoms of retrograde ejaculation during outpatient clinic visits and these events were recorded. Statistical 
differences between the two groups were analyzed and univariate analysis performed using the Fishers exact test 
and Mann-Whitney’s U test. Survival analysis was performed using the Kaplan-Meier method with the log rank 
test. All tests were double sided, and p values < 0.05 were considered to indicate significance.
Results
pre-operative characteristics. The post-chemotherapy, pre-operative patient and tumor characteristics 
of the 150 patients (median age 27 [range 16–66] years) are presented in Table 1. The most common primary 
histology was embryonal carcinoma (n = 99, 66%). There were no statistically significant differences between the 
primary histology in the two groups except for embryonal carcinoma in the L-RRRTM group (p < 0.001). Patients 
with good prognoses according to the International Germ Cell Cancer Collaborative Group (IGCCCG), were 
more likely to undergo L-RRRTM than C-RRRTM (81% vs. 29%; p < 0.001). The majority of patients treated with 
L-RRRTM had clinical stage II disease (68 patients [77%] vs. 31 patients [51%] in the C-RRRTM group; p < 0.05).
Variable
L-RRRTM C-RRRTM
p valueN = 89 N = 61
Age (median, range) yrs 27 (16–66) 28 (16–64) 0.11
Histology compounds testis tumor; n (%)
Seminoma 28 (32) 13 (21) 0.29
Immature teratoma 31 (35) 11 (18) 0.07
Mature teratoma 46 (52) 28 (46) 0.69
Embryonal cell carcinoma 73 (82) 26 (43) <0.001
Chorioncarcinoma 6 (7) 8 (13) 0.11
Yolk sac 41 (46) 17 (28) 0.05
IGCCCG risk score before chemotherapy; n (%)
Good 72 (81) 18 (29) <0.001
Intermediate 12 (13) 26 (43)
Poor 5 (6) 17 (28)
Stage (Royal Marsden); n%
IIA 15 (17) 1 (2) <0.05
IIB 41 (46) 11 (18)
IIC 12 (14) 19 (31)
III 2 (2) 13 (21)
IV 19 (21) 17 (28)
Residual tumor location; n (%)
Para-aortic 61 (69) 25 (41) 0.001
Paracaval 9 (10) 11 (18)
Inter-aorto/caval 16 (18) 21 (34)
Iliacal 3 (3) 4 (7)
Diameter RRTM mm (median range) 20 (5–70) 42 (11–220) <0.001
Table 1. Preoperative patients’ and tumor characteristics. L-RRRTM, laparoscopic resection residual 
retroperitoneal mass. C-RRRTM, conventional resection residual retroperitoneal mass. N/F, necrosis and/or 
fibrosis.
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The most common residual tumor location was para-aortic (86, 57%); 69% in the L-RRRTM group versus 41% 
in the C-RRRTM group (p = 0.001). The median residual tumor size was significantly smaller in the L-RRRTM 
group; 20 (5–70) mm vs. 42 (11–220) mm in the C-RRRTM group (p < 0.001).
operative and outcome characteristics. Eighty-nine patients with a median RRTM mass of 20 (range 
5–70) mm and for whom the vast majority (n = 72, 81%) belonged to the IGCCCG good risk category, were 
scheduled for laparoscopic resection of the RRTM with the intention of resecting it. Para-aortic RRTM location 
was found significantly more often in the group scheduled for L-RRRTM (61 vs. 25 in the C-RRRTM group; 
p < 0.05).
In 14 of 89 patients (15%), a conversion to open, conventional surgery was necessary. As displayed in Fig. 2, 
the conversion rate did not change over the years. In 11 patients, pre-emptive conversions (12%) were performed 
due to technical difficulties (n = 7) and patient-related factors (n = 4). In 3 patients, reactive conversions (3%) 
were performed due to complications that occurred intraoperatively: ureter injury, aortic bleeding, and a bleeding 
of the inferior caval vein, respectively.
In more detailed analyses, operative outcome characteristics for the L-RRRTM (n = 89) and C-RRRTM 
(n = 91)are presented in Table 2. The surgical procedure was significantly shorter in duration in the laparoscopy 
group versus the open group (p < 0.001) with a median of 156 minutes versus 221 minutes.
In the converted group of 14 patients median residual tumor size was 29 (16–70) mm, which was not signif-
icantly different from the median RRTM size in the whole laparoscopy group. Analysis showed, there were no 






Operative time; minutes, median (range) 156 (45–341)* 221 (95–792)*
Postoperative complications; n (%) 17 (19) 18 (30)
None 72 (91) 43 (70)
Wound infection 4 6
Chylous leakage 3 5
Pulmonary infection 1 0




Retrograde ejaculation 2 5
Incisional hernia 0 0
Residual tumor histology; n (%)
N/F 33 (37) 26 (43)
Teratoma +/−N/F 42 (47) 26 (43)
vital carcinoma +/−teratoma 14 (16) 9 (14)
Hospital stay; days, median (range) 2(1–13)* 6 (3–26)*
Table 2. Operative Characteristics: 2005–2015 laparoscopic and conventional surgery. L-RRRTM, laparoscopic 
resection residual retroperitoneal tumor mass. C-RRRTM, conventional resection residual retroperitoneal 
tumor mass. *p < 0.001.
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significant differences in perioperative complications between the 89 patients scheduled for L-RRRTM (5 patients 
[6%]; 1 ureter injury, 4 patients with >500 mL blood loss) and the 61 patients scheduled for C-RRRTM (7 patients 
[12%]; 1 ureter injury, 6 patients with >500 mL blood loss) (p < 0.19). Seventeen postoperative complications 
(19%) occurred in those scheduled for L-RRRTM (n = 89), and 18 postoperative complications (30%) occurred 
in those scheduled for C-RRRTM (n = 61) (p = 0.14). Subgroup analysis showed that patients in the laparoscop-
ically converted RRRTM (LC-RRRTM) and C-RRRTM groups were more likely to develop wound infections, 
chylous leakage, pulmonary infections, and retrograde ejaculation. There were 9 postoperative complications in 
the final L-RRRTM group (n = 75, 12%) versus 8 in the LC-RRRTM group (n = 14, 57%) (p < 0.001) and 18 in the 
C-RRRTM group (n = 61, 30%) (p < 0.05). Also, there were no significant changes in perioperative and postoper-
atieve complication rate in the period 2005–2015 in the L-RRRTM and C-RRRTM group.
The different histologies of the resected RRTM for both groups are presented in Table 2. The median operative 
time in the L-RRRTM group was 156 (35–341) minutes versus 221 (95–792) minutes in the C-RRRTM group 
(p < 0.001). The median length of hospital stay for the L-RRRTM group was 2 (1–13) day vs. 6 (3–26) days in 
the C-RRRTM group (p < 0.001). Excluding the 14 converted procedures, median hospital stay in the L-RRRTM 
group was 1 (1–5) day.
The median follow up for all 150 NSTGCT patients after RRRTM was 79 (range 2–144) months. Twenty-seven 
of 150 patients had recurrences (18%). Eight patients (9%) in the L-RRRTM group and 19 patients (31%) in the 
C-RRRTM group (p < 0.001) had recurrences. The oncological outcome is presented in detail in Table 3.
The histopathology of the 25 resections for recurrent disease showed necrosis/fibrosis in 6 (22%) patients, via-
ble germ cell cancer in 7 patients (26%), teratoma in 12 patients (44%). In 2 patients resection was not performed 
and therefore histology not available. Six patients with viable germ cell cancer at the time of recurrence were in 
the C-RRRTM group versus one patient in the L-RRRTM group. Three of these 6 patients had also viable germ 
cell cancer in their initial RRRTM pathology results. A detailed overview of the 27 patients with recurrences is 
summarized in Table 4.
Of the 27 patients with recurrent disease, 26 (96%) received (combined) treatment; 16 (59%) had surgery 
alone, 9 had (33%) systemic chemotherapy plus surgery, 1 (4%) had only systemic chemotherapy, and 1 (4%) had 
no treatment.
The disease-free survival (DFS) and overall survival (OS) of all patients and those scheduled for L-RRRTM 
(n = 89) and C-RRRTM (n = 61) are presented in Figs 3–6. Significant differences were found in OS and DFS 
between the initially scheduled and final treatment groups.
Discussion
This is currently the largest series published in literature with respect to laparoscopic resection of RRTM after 
cisplatin based combination chemotherapy for metastatic NSTGCTs. In cases of RRTM after chemotherapy for 
metastatic NSTGCT, adjunctive resection of all residual tumor mass is an essential part of the combined treat-
ment to cure these patients3–7. In an earlier pilot study, the Groningen study group showed that the laparoscopic 
approach was feasible in properly selected patients with advanced NSTGCT, with surgical resection compris-
ing of only the resection of the RRTM17. However, the study included a relatively small cohort of patients, and 
longer follow up data are lacking with respect to disease free survival. The current report includes the previously 
described patients17.
Since the introduction of laparoscopic RPLND in 1992, and with the further development and increasingly 
routine use of laparoscopic techniques, the minimally invasive approach is gaining interest in the treatment of 
mainly lower-stage testicular cancer. The nine studies published to date are summarized in Table 5 14,18–25.
In the present study, analysis of the L-RRRTM group was done in parallel with that of the C-RRRTM group. 
The L-RRRTM group consisted of successfully performed laparoscopies (n = 75) as well as the 14 converted pro-
cedures (LC-RRRTM) and the C-RRRTM group (n = 61) included the patients who underwent an open pro-
cedure to resect the RRTM. Statistical analysis performed between these groups should be evaluated in a more 
descriptive fashion since this was not a randomized trial and selection bias indisputably exists, leading to con-
founding factors such as the IGCCCG category and amount of residual disease after chemotherapy.
A significant difference in median RRTM diameter was found between the group scheduled for L-RRRTM 
(20 [range 5–70] mm) versus the group scheduled for C-RRRTM (42 [11–220] mm; p < 0.001). This significant 
difference is in line with the study by Busch et al. where the RRTM diameter was 22 mm in the L-RRRTM group 
versus 68 mm in the C-RRRTM group21. Para-aortic RRTM location was found significantly more often in the 
Variable L-RRRTM N = 89 C-RRRTM N = 61
Follow up; months, median (range) 91 (7–144)# 70 (2–140)#
Recurrence; n (%) 8 (9)a 19 (31)a
Survival status; n (%) NS
No evidence of disease 87 (98) 54 (88)
Alive with disease 1 (1) 1 (2)
Died of disease 1 (1) 5 (8)
Died of other causes 0 1 (2)
Table 3. Outcome characteristics: 2005–2015 laparoscopic and conventional surgery. L-RRRTM, laparoscopic 
resection residual retroperitoneal tumor mass. C-RRRTM, conventional resection residual retroperitoneal 
tumor mass. NS: non significant, #p < 0.05, ap < 0.001.





























1 33# Right 3,4 IV 1 11 interaortocaval N/F 113 9 CTX, RRRTM N/F NED
2 30 Right 1,2 IV 1 17 interaortocaval T,VT 98 11 RRRTM T NED
3 27 Left 1,3 II 1 46 paraaortal T,N/F 97 61 CTX N/A DOD
4 29 Right 1,2 II 1 21 interaortocaval VT 18 14 CTX, RRRTM VT AWD
5 ͨ 41# Right 1,2,3,4 II 1 21 paraaortal T,VT 113 46 RRRTM T NED
6 ͨ 37 Left 1,4 IV 2 29 paraaortal N/F 106 1 CTX, thoracotomy N/F NED
7 ͨ 20 Left 1,2 II 1 16 paracaval N/F 96 9 RRRTM N/F NED
8 ͨ 27 Left 1,3 II 1 29 paraaortal N/F 51 36 RRRTM T NED
C-RRRTM
9 27 Left 1 III 1 17 paraaortal T 109 27 RRRTM T NED
10 37 Right 6 IV 3 15 paracaval T 107 96 RRRTM VT AWD
11 19 Left 1,2,3 IV 2 160 paraaortal T 116 2 Thoracotomy T NED
12 38 Right 3 III 2 15 paraaortal N/F 34 6 Thoracotomy N/F NED
13 28 Right 3 IV 2 80 interaortocaval T,N/F 105 5 CTX, resection mass neck T NED
14 26 Left 1,3 II 2 30 interaortocaval T 96 13 RRRTM T NED
15 24 Left 1,2,3 III 3 31 paracaval T/VT 26 9 Thoracotomy VTª DOD
16 53 Left 5 II 2 80 iliac VT 7 1 No treatment options N/A DOD
17 33 Left 2,3 III 2 84 interaortocaval T/VT 90 5 Thoracotomy T NED
18 22 Left 5 III 2 65 paraaortal T/VT 89 52 CTX, RRRTM VT,T NED
19 21 Right 1,2,3 II 1 47 iliac T 68 10 CTX, RRRTM T DOO
20 31 Left 1 III 1 69 interaortocaval T 89 3 RRRTM T NED
21 28 Right 1,2 IV 3 16 paraaortal N/F 67 7 CTX, RRRTM N/F NED
22 28 Left 3 II 1 35 paraaortal T 19 7 CTX, RTX RRRTM VTª DOD
23 23 Left 3 II 3 220 paraaortal T,VT 58 8 CTX, RRRTM VT NED
24 24 Right 3 III 3 220 interaortocaval T,N/F 45 4 Thoracotomy T NED
25 20 Right 1,2 II 1 29 iliac T 33 10 RRRTM T NED
26 37 Left 3,4 III 1 96 paraaortal T,VT 25 8 Thoracotomy N/F NED
27 23 Left 1,2,3 IV 2 25 paraaortal T,N/F 103 103 RRRTM VT, T NED
Table 4. Characteristics of 27 nonseminomatous testicular cancer patients with relapse. L-RRRTM: 
laparoscopic resection residual retroperitoneal tumor mass, C-RRRTM: conventional resection residual 
retroperitoneal tumor mass, ͨ :converted procedures. #Previously reported17 *Histology: 1: embryonal 
carcinoma, 2: yolk sac tumor, 3: teratoma, 4: seminoma, 5: burnout lesion, 6: unknown. φHistology: N/F: 
necrosis/fibrosis, T: teratoma, VT: viable germ cell cancer, ªEmbryonal rhabdomyosarcoma (transformation 
from mature teratoma). CTX: chemotherapy, RTX: radiotherapy. NED: no evidence of disease, AWD: alive with 
disease; DOD died of disease; DOO died of other causes.
Figure 3. Overall Survival after RRRTM: all patients.
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L-RRRTM group than in the C-RRRTM group. Resection of a residual tumor located para-aortically is technically 
less challenging than resection of a RRTM at an inter-aortocaval or para-caval location.
Although the conversion rate in the literature varied in the past from 0% to up to 75%, the current UMCG 
conversion rate of 15% is in line with current conversion rates varying from 0% to 13%14,18–25. In general, the con-
version rate decreases with surgical experience but increases with the size of the RRTM. The UMCG conversion 
rates in the current series are slightly higher than that of the previous pilot report (15% vs.10%) mainly due to 
pre-emptive factors such as technical difficulties and patient related factors (50% vs. 29%) and in lesser extent due 
to reactive factors (21%). Most indications for conversion described in literature are reactive in nature in contrast 
to this study. For example, obese patients were not always excluded for laparoscopy. A reactive conversion was 
required in only 3 patients.
Figure 6. Disease Free Survival after L- and LC-RRRTM versus C-RRRTM: Log rank p < 0.001.
Figure 4. Overall Survival after L- and LC-RRRTM versus C-RRRTM: Log rank p < 0.01.
Figure 5. Disease Free Survival after RRRTM; all patients.
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Classical RPLND or RRRTM is associated with substantial morbidity. No significant difference was found in 
the perioperative complication rate between L-RRRTM and C-RRRTM group (6% and 12%). In contrast, in an 
open and laparoscopic cohort, Nicolai et al. documented higher intraoperative laparoscopic complication rates of 
37.9% vs. 21.8% (NS)22. A smaller laparoscopic cohort showed a laparoscopic intraoperative morbidity of 33%23. 
The UMCG series showed that concerning the postoperative morbidity there were no significant differences in 
patients undergoing a L-RRRTM (19%) compared to those receiving the C-RRRTM(30%). Although there is a 
tendency for a higher postoperative complication rate in patients undergoing an open procedure which can be 
explained by the more extensive retroperitoneal disease in these patients and/or the anatomical location of the 
residual tumor mass. In the same manner, Nicolai et al. also documented no significant differences between these 
groups; 14% vs. 9%22.
The median operative time in the present study was significantly shorter in the L-RRRTM group versus the 
C-RRRTM group. This is to be expected since the latter group had more extensive disease and larger RRTM vol-
ume; the median residual tumor mass was 20 (range 16–66) mm in the L-RRRTM group, and 42 (range 11–220) 
mm in the C-RRRTM group. In contrast, other more recent studies reported longer operative times for laparo-
scopic procedures of 234, 294, and 439 minutes23–25. Nicolai et al. reported equivalent operative times (212 vs. 
232 min, p = 0.3)22. A study originating from Japan reported not only longer operative times in the laparoscopic 
group, but also in the open group (439 vs. 408 minutes)25.
As expected, the L-RRRTM group required a significantly shorter hospital stay compared to the C-RRRTM 
group (medians of 2 day vs. 6 days; p < 0.001). In contrast to the short hospital stay for the laparoscopy patients in 
this series, the median hospital stay in other studies was longer after L-RRRTM, ranging from 3–7 days (Table 5). 
Nicolai et al. also compared the L-RRRTM group versus the C-RRRTM group and documented a median hospital 
stay of 6 vs. 11.5 days (p < 0.01)22.
Thus far, there are no long-term outcome data in advanced nonseminomatous germ cell tumors comparing 
laparoscopic RRRTM to conventional RRRTM. After a median follow-up of 79 months, 27 patients (18%) devel-
oped recurrent disease; 19 in the C-RRRTM group (31%) and 8 in the L-RRRTM (9%): 4 of these 8 recurrences 
occurred in patients who underwent converted procedures. Reasons for conversion in these 4 patients were aortic 
injury, injury to the caval vein, and two technical difficulties due to extensive fibrosis which could be indicative of 
more extensive disease. Other laparoscopic surgeries for resection of residual masses also showed low recurrence 
rates (Table 5). However, most reports consist of only small patient series and predominantly include patients 
with good prognosis disease and small residual tumor masses, with a limited follow-up duration14,18–20.
When selecting patients for L-RRRTM, factors other than merely the size of the mass are important. Selection 
criteria are not absolute and these criteria are dynamic; first, in relation to developing skills and second, the 
anatomical site of the residual mass. Large residual masses greater than 5 cm might be eligible for a laparoscopic 
approach based on the laparoscopic experience of the surgical oncologist and the anatomical location.
Surgeons can now also perform robotic-assisted RRRTM26,27. Within a few years, robotic surgery might 
extend the indication for L-RRRTM, even for more challenging RRTM. L-RRRTM meets or exceeds the results 




























— 0 0 (0) 28 (17) 243 4 58 (3–121) 1 (1)
Albqami14 2005 59 43 IIB16 IIC — 0 9 (15) 11 (19) 234 4 53 1 (2)
Calestroupat18 2009 26 16 IIA/B13 II C 3.4 (2–6) 5 (2.6) 1(20%) 4 (80%) 9 (35) none 183 5 27 (14–36) none



















(15–31) 3 (4.5) 2 (67%) 1 (33%) 1 (1.5) 3 (4.5) 234 3 21 none
Nakamura25 2016 14 14 IIA/B 25 (18–30) 0 0 7 (50) 439 1 36 none
UMCG series 2017 89






(5–57) 14 (16%) 11 (78%) 3 (22%) 5 (6%) 9 (12%) 148 1 79 (7–144) 3 (4%)
Table 5. Comparison series of laparoscopic RRRTM.
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from most open conventional surgeries and should always be considered as a viable alternative in the resection of 
residual tumor mass after cisplatin-containing chemotherapy for locally advanced testicular cancer, offering less 
morbidity, a favorable cosmetic outcome for the patient, and a shorter hospital stay. The study showed that lapa-
roscopic resection of RRTM in proper selected and well-defined patients is a feasible, non inferior procedure to a 
conventional laparotomy for the resection of low volume RRTM with a longterm recurrence rate of 9%. Although 
a randomized trial comparing both treatment modalities, L-RRRTM vs. C-RRRTM, is the gold standard to proof 
the superiority of this minimally invasive approach for low-volume disease and therefore the results should be 
interpreted with caution. A multidisciplinary expert testicular cancer team with an experienced (oncological) 
laparoscopist is essential to achieve these peri-operative and longterm results and this has to be taken into account 
in the discussion of treatment options, L-RRRTM vs. C-RRRTM, with the testicular cancer patient.
In conclusion, with a robust sample size and a median follow-up duration of more than 6 years, this study 
confirms that laparoscopic resection of well-defined RRTM after cisplatin combination chemotherapy for meta-
static nonseminomatous testicular cancer is a feasible procedure and appears to be an oncologically safe option in 
appropriately selected patients, offering oncological non inferior results compared to conventional surgery, with 
less morbidity, a shorter hospital stay, and a favorable cosmetic outcome for the patient with testicular cancer. 
Despite the fact that technical boundaries are gradually expanding due to developing skills and technical inno-
vations it can be stated that residual masses up to 5 cm and located para-aortically seem suitable for laparoscopic 
resection. These surgical procedures, L-RRRTM and C-RRRTM, should preferably take place in a high volume 
tertiary referral centers for the treatment of testicular cancer.
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